Our understanding of the infection risks presented by tumour necrosis factor (TNF)
antagonists has continued to evolve in the 10 years since these drugs were first introduced …

Tumor necrosis factor-alpha (TNFα) antagonists including antibodies and soluble receptors
have shown remarkable efficacy in various immune-mediated inflammatory diseases (IMID) …

Abstract Uveitis is a frequent (20–50%) and early feature of sarcoidosis. Typical sarcoid
uveitis presents with mutton-fat keratic precipitates, iris nodules, and anterior and posterior …

Objective. TNF blockers have been recently evaluated for treating refractory sarcoidosis and
could be efficient. However, several cases of sarcoidosis have been diagnosed during anti …

Sarcoidosis is an uncommon systemic inflammatory disorder characterized by noncaseating
granulomatous inflammation that most commonly affects the lungs, intrathoracic lymph …

About half of patients with sarcoidosis will need systemic therapy for their disease. Oral
glucocorticoids are the standard first-line treatment for sarcoidosis. With time, patients might …

Background Long‐term corticosteroid therapy is the standard of care for treatment of cardiac
sarcoidosis (CS). The efficacy of long‐term corticosteroid‐sparing immunosuppression in …

Thoracic sarcoidosis is the most common form of sarcoidosis, encompassing a
heterogeneous group of patients with a wide range of clinical features and associated …

Sarcoidosis is a multi-system disease of unknown etiology characterized by granuloma
formation in various organs (especially lung and mediastinohilar lymph nodes). In more than …

Sarcoidosis is a systemic inflammatory disease with a predilection for the respiratory system.
Although most patients enter remission and have good long-term outcomes, up to 20 …